Cover ImageSALE
市場調查報告書

自體免疫疾病及發炎性疾病的免疫調節藥物的全球市場:2016∼2020年

Global Autoimmune and Inflammatory Immunomodulators Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 387468
出版日期 內容資訊 英文 98 Pages
訂單完成後即時交付
價格
Back to Top
自體免疫疾病及發炎性疾病的免疫調節藥物的全球市場:2016∼2020年 Global Autoimmune and Inflammatory Immunomodulators Market 2016-2020
出版日期: 2016年11月03日 內容資訊: 英文 98 Pages
簡介

全球自體免疫疾病及發炎性疾病的免疫調節藥物市場預計2016∼2020年以7.01%的年複合成長率擴大。免疫調節藥物在市面上有許多調整免疫系統的藥物,不過,因為沒有治癒類風濕性關節炎和潰瘍性大腸炎,克隆氏症等部分疾病的藥物,現在還有龐大的未滿足需求。

本報告提供全球自體免疫疾病及發炎性疾病的免疫調節藥物市場相關調查,至2020年的成長預測,供應商趨勢,各地區趨勢,及加入此市場的主要供應商簡介等彙整資料。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 自體免疫疾病和炎症性疾病

  • 類風濕性關節炎
  • IBD
  • 主要的免疫調節藥物

第6章 產品研發線

第7章 市場情況

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第8章 各疾病市場區隔

  • 類風濕性關節炎
  • IBD

第9章 各分子類型市場區隔

  • 生物學的免疫調節藥物
  • 小分子免疫調節藥物

第10章 各地區市場區隔

  • 各地區市場
  • 南北美洲
  • 歐洲、中東、非洲
  • 亞太地區

第11章 市場趨勢

  • TNF Alpha抑制劑及B細胞抑制劑的普及
  • 使用創新技術的新治療藥的開發
  • 改良的診斷工具使尋求治療的人口增加

第12章 促進要素的影響

第13章 市場課題

  • 開發中藥物的中斷使收益的大幅度減少
  • 替代治療方法越來越受歡迎阻礙市場成長
  • 藥物的副作用

第14章 促進要素與課題的影響

第15章 市場趨勢

第16章 供應商環境

  • 競爭模式
  • 其他值得注意的供應商

第17章 主要供應商分析

  • AbbVie
  • Johnson & Johnson
  • Amgen
  • F. Hoffmann-La Roche
  • Pfizer

第18章 附錄

第19章 關於Technavio

目錄
Product Code: IRTNTR10705

About Autoimmune and Inflammatory Immunomodulators

Immunomodulators are the drugs that help to regulate the immune system. These drugs either stimulate the weak immune systems or moderate the overactive immune systems. Though many drugs are available in the market, there still exists a huge unmet need in the autoimmune and inflammatory immunomodulators market as there are no medicines that provide complete cure to some diseases such as rheumatoid arthritis, ulcerative colitis, and Crohn's disease.

Technavio's analysts forecast the global autoimmune and inflammatory immunomodulators market to grow at a CAGR of 7.01% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global autoimmune and inflammatory immunomodulators market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Autoimmune and Inflammatory Immunomodulators Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • AbbVie
  • Johnson & Johnson
  • Amgen
  • F. Hoffmann-La Roche
  • Pfizer

Other Prominent Vendors

  • AstraZeneca
  • Avaxia Biologics
  • Biogen Idec
  • Bristol-Myers Squibb
  • Boehringer Ingelheim
  • Eli Lilly
  • Enlivex Therapeutics
  • Gilead Sciences
  • Immune Pharmaceuticals
  • Merck
  • Mitsubishi Tanabe Pharma
  • Neovacs
  • Prometheus Laboratories
  • Sandoz
  • Sanofi
  • Swedish Orphan Biovitrum
  • Takeda Pharmaceuticals
  • UCB

Market driver

  • Development of novel therapies using innovative technologies.
  • For a full, detailed list, view our report

Market challenge

  • Discontinuation of drugs under development leading to substantial loss in revenue.
  • For a full, detailed list, view our report

Market trend

  • Advent of biosimilars expected to improve the treatment rates.
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Autoimmune and inflammatory diseases

  • Rheumatoid arthritis
  • IBD
  • Top immunomodulators for rheumatoid arthritis and IBD

PART 06: Pipeline portfolio

PART 07: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 08: Market segmentation by type of disease

  • Global rheumatoid arthritis immunomodulators market
  • Global IBD immunomodulators market

PART 09: Market segmentation by molecule type

  • Global autoimmune and inflammatory biologic immunomodulators market
  • Global autoimmune and inflammatory small molecule immunomodulators market

PART 10: Geographical segmentation

  • Global autoimmune and inflammatory immunomodulators market by geography 2015-2020
  • Autoimmune and inflammatory immunomodulators market in Americas
  • Autoimmune and inflammatory immunomodulators market in EMEA
  • Autoimmune and inflammatory immunomodulators market in APAC

PART 11: Market drivers

  • Strong adoption of TNF-alpha inhibitors and B-cell inhibitors
  • Development of novel therapies using innovative technologies
  • Improved diagnostic tools increase the treatment-seeking population

PART 12: Impact of drivers

PART 13: Market challenges

  • Discontinuation of drugs under development leading to substantial loss of revenue
  • Growing popularity of alternative treatment procedures hinders the market growth
  • Adverse effects of the drugs

PART 14: Impact of drivers and challenges

PART 15: Market trends

  • Emergence of oral agents likely to improve patient outcomes
  • Advent of biosimilars expected to improve the treatment rates
  • Focus on regenerative medicines
  • Strategic alliances and acquisitions

PART 16: Vendor landscape

  • Competitive scenario
  • Other prominent vendors

PART 17: Key vendor analysis

  • AbbVie
  • Johnson & Johnson
  • Amgen
  • F. Hoffmann-La Roche
  • Pfizer

PART 18: Appendix

  • List of abbreviations

PART 19: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Different classes of immunosuppressant drugs based on their mechanism of action
  • Exhibit 03: Key buying criteria for global autoimmune and inflammatory immunomodulators market 2015
  • Exhibit 04: Key customer segments of autoimmune and inflammatory immunomodulators market
  • Exhibit 05: Etiology of autoimmune diseases
  • Exhibit 06: Pipeline portfolio: Rheumatoid arthritis immunomodulators
  • Exhibit 07: Pipeline portfolio: Ulcerative colitis immunomodulators
  • Exhibit 08: Pipeline portfolio: Crohn's disease immunomodulators
  • Exhibit 09: Global autoimmune and inflammatory immunomodulators market snapshot: Developed and emerging markets 2015
  • Exhibit 10: Factors influencing global autoimmune and inflammatory immunomodulators market
  • Exhibit 11: Approval and patent expiries of top-selling biologics
  • Exhibit 12: Impact of factors affecting the market 2015 and 2020
  • Exhibit 13: Global autoimmune and inflammatory immunomodulators market 2015-2020 ($ billions)
  • Exhibit 14: Five forces analysis
  • Exhibit 15: Segmentation of global autoimmune and inflammatory immunomodulators by type of disease based on revenue 2015
  • Exhibit 16: Global autoimmune and inflammatory immunomodulators market by disease type 2015-2020
  • Exhibit 17: Global rheumatoid arthritis immunomodulators market 2015-2020 ($ billions)
  • Exhibit 18: Opportunities across rheumatoid arthritis industry
  • Exhibit 19: Global IBD immunomodulators market 2015-2020 ($ billions)
  • Exhibit 20: Global IBD therapeutics market segmentation growth lifecycle analysis
  • Exhibit 21: Global IBD immunomodulators market by disease type 2015-2020
  • Exhibit 22: Global ulcerative colitis immunomodulators market 2015-2020 ($ billions)
  • Exhibit 23: Global Crohn's disease immunomodulators market 2015-2020 ($ billions)
  • Exhibit 24: Comparative graph of global autoimmune and inflammatory immunomodulators market by molecule type ($ billions)
  • Exhibit 25: Global autoimmune and inflammatory biologic immunomodulators market 2015-2020 ($ billions)
  • Exhibit 26: Biologicals approvals by the US FDA
  • Exhibit 27: Global rheumatoid arthritis biologic immunomodulators market 2015-2020 ($ billions)
  • Exhibit 28: Global IBD biologic immunomodulators market 2015-2020 ($ billions)
  • Exhibit 29: Global autoimmune and inflammatory small molecule immunomodulators market 2015-2020 ($ billions)
  • Exhibit 30: Global autoimmune and inflammatory immunomodulators market by geography 2015-2020
  • Exhibit 31: Global autoimmune and inflammatory immunomodulators market segmentation by geography 2015-2020 ($ billions)
  • Exhibit 32: Global share of autoimmune and inflammatory immunomodulators market by geography 2015
  • Exhibit 33: Global autoimmune and inflammatory immunomodulators market segmentation by region: Market growth lifecycle analysis 2015
  • Exhibit 34: Global autoimmune and inflammatory immunomodulators market: Country analysis based on revenue and growth rate
  • Exhibit 35: Opportunity analysis of autoimmune and inflammatory immunomodulators market in Americas
  • Exhibit 36: Autoimmune and inflammatory immunomodulators market in Americas 2015-2020 ($ billions)
  • Exhibit 37: Opportunity analysis of autoimmune and inflammatory immunomodulators market in EMEA
  • Exhibit 38: Autoimmune and inflammatory immunomodulators market in EMEA 2015-2020 ($ billions)
  • Exhibit 39: Opportunity analysis of autoimmune and inflammatory immunomodulators market in APAC
  • Exhibit 40: Autoimmune and inflammatory immunomodulators market in APAC 2015-2020 ($ billions)
  • Exhibit 41: Sales performance of key TNF-alpha inhibitors and B-cell inhibitors ($ billions)
  • Exhibit 42: Key vendors: Developing novel therapies
  • Exhibit 43: Key developments leading to improved diagnostics
  • Exhibit 44: Impact of drivers
  • Exhibit 45: List of few immunomodulators that were discontinued from development or market
  • Exhibit 46: CAM therapies for rheumatoid arthritis
  • Exhibit 47: Usage of CAM therapies in US adults
  • Exhibit 48: List of CAM therapies and items used in Crohn's disease and ulcerative colitis
  • Exhibit 49: List of adverse side effects associated with rheumatoid arthritis
  • Exhibit 50: Impact of drivers and challenges
  • Exhibit 51: Key marketed and pipeline oral agents
  • Exhibit 52: List of few biosimilars under development for various indications
  • Exhibit 53: List of few regenerative medicines under development for rheumatoid arthritis and IBD
  • Exhibit 54: Key deals in global immunomodulators market
  • Exhibit 55: Market share of key vendors 2015
  • Exhibit 56: Geographical presence of key vendors
  • Exhibit 57: Competitive scenario of global autoimmune and inflammatory immunomodulators market vendors 2015-2020
  • Exhibit 58: AbbVie: Strength assessment
  • Exhibit 59: AbbVie: Strategy assessment
  • Exhibit 60: AbbVie: Opportunity assessment
  • Exhibit 61: AbbVie: YoY growth and revenue of Humira 2013-2015 ($ billions)
  • Exhibit 62: Johnson & Johnson: Strength assessment
  • Exhibit 63: Johnson & Johnson: Strategy assessment
  • Exhibit 64: Johnson & Johnson: Opportunity assessment
  • Exhibit 65: Johnson & Johnson: YoY revenue and growth rate of Remicade 2013-2015 ($ billions)
  • Exhibit 66: Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria 2013-2015 ($ billions)
  • Exhibit 67: Amgen: Strength assessment
  • Exhibit 68: Amgen: Strategy assessment
  • Exhibit 69: Amgen: Opportunity assessment
  • Exhibit 70: Amgen: YoY revenue and growth rate of Enbrel (in the US and Canada) 2013-2015 ($ billions)
  • Exhibit 71: F. Hoffmann-La Roche: Strength assessment
  • Exhibit 72: F. Hoffmann-La Roche: Strategy assessment
  • Exhibit 73: F. Hoffmann-La Roche: Opportunity assessment
  • Exhibit 74: F. Hoffmann-La Roche: YoY growth and revenue of MabThera/Rituxan for immunology segment 2013-2015 ($ billions)
  • Exhibit 75: F. Hoffmann-La Roche: YoY growth and revenue of Actemra/RoActemra for immunology segment 2013-2015 ($ billions)
  • Exhibit 76: Pfizer: Strength assessment
  • Exhibit 78: Pfizer: Strategy assessment
  • Exhibit 79: Pfizer: Opportunity assessment
  • Exhibit 80: Pfizer: Global autoimmune and inflammatory immunomodulators revenues 2014-2015 ($ billions)
Back to Top